Xarelto Related Published Studies
Well-designed clinical trials related to Xarelto (Rivaroxaban)
Relationship between time in therapeutic range and comparative treatment effect
of rivaroxaban and warfarin: results from the ROCKET AF trial. [2014]
Outcomes of temporary interruption of rivaroxaban compared with warfarin in
patients with nonvalvular atrial fibrillation: results from the rivaroxaban once
daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for
prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). [2014]
Efficacy and safety of rivaroxaban compared with warfarin in patients with
peripheral artery disease and non-valvular atrial fibrillation: insights from
ROCKET AF. [2014]
Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial
fibrillation in relation to the CHADS2 score: a subgroup analysis of the J-ROCKET
AF trial. [2014]
Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with
nonvalvular atrial fibrillation: a subgroup analysis of J-ROCKET AF. [2014]
Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism
after total hip replacement. A randomised, controlled trial. [2013]
Oral rivaroxaban after symptomatic venous thromboembolism: the continued
treatment study (EINSTEIN-extension study). [2011]
Rationale and design of the Anti-Xa therapy to lower cardiovascular events in
addition to standard therapy in subjects with acute coronary
syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a
randomized, double-blind, placebo-controlled study to evaluate the efficacy and
safety of rivaroxaban in subjects with acute coronary syndrome. [2011]
Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee
arthroplasty: a meta-analysis of randomized controlled trials. [2010]
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS
ACS-TIMI 46): a randomised, double-blind, phase II trial. [2009]
A dose-ranging study evaluating once-daily oral administration of the factor Xa
inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep
vein thrombosis: the Einstein-DVT Dose-Ranging Study. [2008]
Randomized, Double-Blind, Crossover Study to Investigate the Effect of Rivaroxaban on QT-Interval Prolongation. [2008]
Well-designed clinical trials possibly related to Xarelto (Rivaroxaban)
Aspirin for prevention and treatment of venous thromboembolism. [2014]
New oral anticoagulants and the risk of intracranial hemorrhage: traditional and
Bayesian meta-analysis and mixed treatment comparison of randomized trials of new
oral anticoagulants in atrial fibrillation. [2013]
The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to
Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With
Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51). [2013]
Anticoagulating obese patients in the modern era. [2011]
Other research related to Xarelto (Rivaroxaban)
An open-label, randomized, controlled, multicenter study exploring two treatment
strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment
strategy in subjects with atrial fibrillation who undergo percutaneous coronary
intervention (PIONEER AF-PCI). [2015]
Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of
venous thromboembolism after total hip or knee arthroplasty. [2014]
Major bleeding with dabigatran and rivaroxaban in patients with atrial
fibrillation: a real-world setting. [2014]
Comparison of three-factor and four-factor prothrombin complex concentrates
regarding reversal of the anticoagulant effects of rivaroxaban in healthy
volunteers. [2014]
Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and
trial sequential analysis of randomized clinical trials. [2013]
Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the
prevention of recurrent venous thromboembolism: a U.S. perspective. [2013]
Patient-reported treatment satisfaction with oral rivaroxaban versus standard
therapy in the treatment of acute symptomatic deep-vein thrombosis. [2013]
Open-label, randomized study of the effect of rivaroxaban with or without
acetylsalicylic acid on thrombus formation in a perfusion chamber. [2013]
Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary
syndrome (from ATLAS ACS 2-TIMI 51). [2013]
Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in
the management of patients with nonvalvular atrial fibrillation. [2013]
Reduction of stent thrombosis in patients with acute coronary syndromes treated
with rivaroxaban in ATLAS-ACS 2 TIMI 51. [2013]
Rivaroxaban for the treatment of acute coronary syndromes. [2013]
Effect of non-specific reversal agents on anticoagulant activity of dabigatran
and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. [2012]
Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary
syndromes. [2012]
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran,
rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. [2012]
The use of rivaroxaban for short- and long-term treatment of venous
thromboembolism. [2012]
[Effect of rivaroxaban on risk of bleeding after total knee arthroplasty]. [Article in Chinese] [2011]
Prevention of stroke and systemic embolism with rivaroxaban compared with
warfarin in patients with non-valvular atrial fibrillation and moderate renal
impairment. [2011]
Safety and efficacy of rivaroxaban for thromboprophylaxis following lower limb
surgery: an update. [2011]
A systematic review of rivaroxaban versus enoxaparin in the prevention of venous
thromboembolism after hip or knee replacement. [2011]
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or
knee arthroplasty: Results of separate pooled analyses of phase III multicenter
randomized trials. [2010]
Other possibly related research studies
Efficacy and safety of novel oral anticoagulants for treatment of acute venous
thromboembolism: direct and adjusted indirect meta-analysis of randomised
controlled trials. [2012]
Emerging oral anticoagulants for stroke prevention in patients with non-valvular
atrial fibrillation. [2012]
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on
apixaban. [2012]
Randomized controlled trials of new oral anticoagulants for stroke prevention in
atrial fibrillation. [2012]
Novel anticoagulants for non-valvular atrial fibrillation. [2012]
Medical cost reductions associated with the usage of novel oral anticoagulants vs
warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and
ARISTOTLE trials. [2012]
Newer anticoagulants in cardiovascular disease: a systematic review of the
literature. [2012]
The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next
Diadochian War? [2012]
Antiplatelet agents and anticoagulants for hypertension. [2011]
Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis
of the Dabigatran versus Warfarin clinical trial. [2011]
New options for stroke prevention in atrial fibrillation. [2010]
New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides,
direct thrombin inhibitors, direct Xa inhibitors. [2010]
The new oral anticoagulants, do they change the benefit vs. risk for
thromboprophylaxis in association to ambulatory surgery? [2010]
Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis
of randomized trials. [2014]
Treatment discontinuations with new oral agents for long-term anticoagulation:
insights from a meta-analysis of 18 randomized trials including 101,801 patients. [2014]
New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics? [2014]
Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal
anti-inflammatory drugs or aspirin. [2014]
Comparisons between novel oral anticoagulants and vitamin K antagonists in
patients with CKD. [2014]
Development of a tool to identify patients' preference for vitamin K antagonist
or direct oral anticoagulant therapy. [2014]
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K
antagonists in the treatment of acute symptomatic venous thromboembolism: a
systematic review and meta-analysis. [2014]
New oral anticoagulants and the cancer patient. [2014]
New oral anticoagulants are not superior to warfarin in secondary prevention of
stroke or transient ischemic attacks, but lower the risk of intracranial
bleeding: insights from a meta-analysis and indirect treatment comparisons. [2013]
Benefit-to-harm ratio of thromboprophylaxis for patients undergoing major
orthopaedic surgery. A systematic review. [2014]
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with
vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. [2014]
Is there a need for "triple therapy"? Role of anticoagulation with dual
antiplatelet therapy in acute coronary syndromes (ATLAS Study & TRAP Study). [2013]
Cost-effectiveness of new oral anticoagulants in the prevention of stroke in
patients with atrial fibrillation. [2013]
New oral anticoagulants in elderly patients. [2013]
Bleeding and antidotes in new oral anticoagulants. [2013]
NOACs for thromboprophylaxis in medical patients. [2013]
Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery. [2013]
New anticoagulants in the treatment of patients with cancer-associated venous
thromboembolism. [2013]
New oral anticoagulants for the treatment of venous thromboembolism. [2013]
Novel oral anticoagulants in secondary prevention of stroke. [2013]
Disadvantages of VKA and requirements for novel anticoagulants. [2013]
Do women bleed more than men when prescribed novel oral anticoagulants for venous
thromboembolism? A sex-based meta-analysis. [2013]
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or
systemic embolism in patients with atrial fibrillation. [2013]
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new
anticoagulants for stroke prevention in patients with nonvalvular atrial
fibrillation. [2013]
Efficacy and safety of new oral anticoagulants for extended treatment of venous
thromboembolism: systematic review and meta-analyses of randomized controlled
trials. [2013]
Stroke prevention in atrial fibrillation patients with chronic kidney disease. [2013]
Oral antithrombotic therapy in atrial fibrillation associated with acute or
chronic coronary artery disease. [2013]
Cost-effectiveness of new oral anticoagulants compared with warfarin in
preventing stroke and other cardiovascular events in patients with atrial
fibrillation. [2013]
Balancing risk and benefit in venous thromboembolism trials: concept for a
bivariate endpoint trial design and analytic approach. [2013]
[Electrical cardioversion for non-valvular atrial fibrillation--underestimated
risk for thromboembolic complications?]. [Article in German] [2013]
The efficacy and safety of oral anticoagulants in warfarin-suitable patients with
nonvalvular atrial fibrillation: systematic review and meta-analysis. [2013]
Use of new oral anticoagulants in antiphospholipid syndrome. [2013]
Potential impact of new oral anticoagulants on the management of atrial
fibrillation-related stroke in primary care. [2013]
Target-specific oral anticoagulants in atrial fibrillation: results of phase III
trials and comments on sub-analyses. [2013]
Safety of new oral anticoagulants with dual antiplatelet therapy in patients with
acute coronary syndromes. [2013]
Eligibility and preference of new oral anticoagulants in patients with atrial
fibrillation: comparison between patients with versus without stroke. [2014]
New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics? [2014]
Aspirin combined with mechanical measures to prevent venous thromboembolism after
total knee arthroplasty: a randomized controlled trial. [2014]
Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer
oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation
and proposal of a management algorithm. [2014]
Beyond warfarin: a patient-centered approach to selecting novel oral
anticoagulants for stroke prevention in atrial fibrillation. [2014]
|